Cargando…

Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)

The Billroth IV consensus was developed during a consensus meeting of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of Interventional Radiology (ÖGIR) held on the 26th of November 2022 in Vienna. Based on international recommendations and considering recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandorfer, Mattias, Aigner, Elmar, Cejna, Manfred, Ferlitsch, Arnulf, Datz, Christian, Gräter, Tilmann, Graziadei, Ivo, Gschwantler, Michael, Hametner-Schreil, Stephanie, Hofer, Harald, Jachs, Mathias, Loizides, Alexander, Maieron, Andreas, Peck-Radosavljevic, Markus, Rainer, Florian, Scheiner, Bernhard, Semmler, Georg, Reider, Lukas, Reiter, Silvia, Schoder, Maria, Schöfl, Rainer, Schwabl, Philipp, Stadlbauer, Vanessa, Stauber, Rudolf, Tatscher, Elisabeth, Trauner, Michael, Ziachehabi, Alexander, Zoller, Heinz, Fickert, Peter, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Consensus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319704/ https://www.ncbi.nlm.nih.gov/pubmed/37358642 http://dx.doi.org/10.1007/s00508-023-02229-w

Ejemplares similares

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
por: Reiberger, Thomas, et al.
Publicado: (2017)

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test
por: Hametner, Stephanie, et al.
Publicado: (2016)

Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
por: Jachs, Mathias, et al.
Publicado: (2021)

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience
por: Bucsics, Theresa, et al.
Publicado: (2018)

The impact of COVID-19 on liver transplantation programs in Austria
por: Hartl, Lukas, et al.
Publicado: (2022)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

Biodegradable biliopancreatic stents could help conserve health care resources during the COVID-19 pandemic: An observational multicenter study
por: Maieron, Andreas, et al.
Publicado: (2023)

Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
por: Semmler, Georg, et al.
Publicado: (2021)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2016)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites
por: Mandorfer, Mattias, et al.
Publicado: (2014)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
por: Bucsics, Theresa, et al.
Publicado: (2022)

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function
por: Scheiner, Bernhard, et al.
Publicado: (2018)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria
por: Pfisterer, Nikolaus, et al.
Publicado: (2020)

Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence
por: Steininger, Lisa, et al.
Publicado: (2020)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Billroth
Publicado: (1877)

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
por: Jachs, Mathias, et al.
Publicado: (2022)

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2018)

Billroth's Surgery
Publicado: (1873)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Outcomes of an HCV elimination program targeting the Viennese MSM population
por: Jachs, Mathias, et al.
Publicado: (2021)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

Gastric cancer surgery: Billroth I or Billroth II for distal gastrectomy?
por: Sah, Birendra K, et al.
Publicado: (2009)

HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic
por: Hartl, Lukas, et al.
Publicado: (2022)

Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms
por: Fabian, Elisabeth, et al.
Publicado: (2015)

Billroth’s Clinic in 1882
Publicado: (1883)

Cannot write session to /tmp/vufind_sessions/sess_23u3optpprmpgi5vkdnrhppiqe